Drugs / MK-0752
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT01295632 | Feb 2011 → Dec 2013 | cancer of unknown primary site | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT01243762 | Nov 2010 → Dec 2012 | cancer | Merck Sharp & Dohme LLC | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT01098344 | Apr 2010 → Oct 2014 | malignant pancreatic neoplasm | Cancer Research UK | Completed | No outcome recorded |
| Phase 1 | NCT00572182 | Jul 2008 → Feb 2011 | central nervous system cancer | Pediatric Brain Tumor Consortium | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT00106145 | Apr 2005 → Aug 2011 | female breast carcinoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT00100152 | Feb 2005 → Sep 2006 | T-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, myelodysplastic syndrome, myeloid leukemia | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00645333 | Mar 2008 → Jan 2010 | breast cancer | University of Michigan Rogel Cancer Center | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT00756717 | Feb 2008 → Dec 2011 | breast cancer | Loyola University | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT00803894 Comparator | Dec 2008 → Jan 2009 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-0752 | “A Cancer Research UK Phase I Trial of an Oral Notch Inhibitor (MK-0752) in Combination With Gemcitabine in Patients With Stage III and IV Pancreatic Cancer” NCT01098344 ↗11“This study examined the effects of GSI MK-0752 on blood and hair follicle transcriptomes in healthy volunteers.” PMID 26765077 ↗ Feb 2016 “MK-0752 is a potent, oral inhibitor of γ-secretase, an enzyme required for Notch pathway activation.” PMID 22547604 ↗ Apr 2012 |
| Action | Inhibit | “Notch Inhibitor” NCT00100152 ↗ |
| Modality | Small molecule | — CHEMBL4205422 ↗ |
| Route | Oral | “MK-0752 is a potent, oral inhibitor of γ-secretase, an enzyme required for Notch pathway activation.” PMID 22547604 ↗ Apr 2012 |